Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.
Company profile
Ticker
LLY, LLY-GF, LLY-GM, LLY-SE
Exchange
Website
CEO
David Ricks
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LILLY ELI & CO, LILLY ELI & CO ET AL
SEC CIK
Corporate docs
Subsidiaries
Akouos Securities Corporation • Akouos, Inc. • Alnara Pharmaceuticals, Inc. • Andean Technical Operations • ARMO Biosciences, Inc. • Avid Radiopharmaceuticals, Inc. • CoLucid Pharmaceuticals, Inc. • Compania Farmaceutica Eli Lilly de Centro America S.A. • Dermira, Inc. • DICE Alpha Inc. ...
IRS number
350470950
LLY stock data
Latest filings (excl ownership)
PX14A6G
Letter to shareholders
11 Apr 24
PX14A6G
Letter to shareholders
28 Mar 24
PX14A6G
Letter to shareholders
28 Mar 24
PX14A6G
Letter to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
22 Mar 24
DEF 14A
Definitive proxy
22 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Other Events
9 Feb 24
424B2
Prospectus for primary offering
8 Feb 24
Transcripts
LLY
Earnings call transcript
2023 Q4
6 Feb 24
LLY
Earnings call transcript
2023 Q3
2 Nov 23
LLY
Earnings call transcript
2023 Q2
8 Aug 23
LLY
Earnings call transcript
2023 Q1
27 Apr 23
LLY
Earnings call transcript
2022 Q4
2 Feb 23
LLY
Earnings call transcript
2022 Q3
1 Nov 22
LLY
Earnings call transcript
2022 Q2
4 Aug 22
LLY
Earnings call transcript
2022 Q2
7 Jun 22
LLY
Earnings call transcript
2022 Q1
28 Apr 22
LLY
Earnings call transcript
2021 Q4
3 Feb 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.38 bn | 2.38 bn | 2.38 bn | 2.38 bn | 2.38 bn | 2.38 bn |
Cash burn (monthly) | 104.57 mm | 19.72 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 720.56 mm | 135.87 mm | n/a | n/a | n/a | n/a |
Cash remaining | 1.66 bn | 2.24 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 15.9 | 113.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
53.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2738 |
Opened positions | 336 |
Closed positions | 496 |
Increased positions | 1029 |
Reduced positions | 1029 |
13F shares | Current |
---|---|
Total value | 274.77 tn |
Total shares | 512.59 mm |
Total puts | 1.82 mm |
Total calls | 1.20 mm |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 71.61 mm | $41.74 tn |
PNC PNC Financial Services | 51.71 mm | $30.14 tn |
STT State Street | 33.79 mm | $19.70 tn |
FMR | 32.85 mm | $19.15 tn |
Capital World Investors | 26.95 mm | $15.71 tn |
Primecap Management | 22.20 mm | $12.94 tn |
T. Rowe Price | 21.83 mm | $12.72 bn |
JPM JPMorgan Chase & Co. | 19.27 mm | $11.24 tn |
MS Morgan Stanley | 12.66 mm | $7.38 tn |
Wellington Management | 11.78 mm | $6.87 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Alvarez Ralph | Common Stock | Grant | Acquire A | No | No | 750.77 | 16 | 12.01 k | 54,029 |
15 Apr 24 | Hedley Mary Lynne | Common Stock | Grant | Acquire A | No | No | 750.77 | 13 | 9.76 k | 1,477 |
15 Apr 24 | Luciano Juan R | Common Stock | Grant | Acquire A | No | No | 750.77 | 20 | 15.02 k | 15,678 |
15 Apr 24 | Kimberly H Johnson | Common Stock | Grant | Acquire A | No | No | 750.77 | 13 | 9.76 k | 2,627 |
15 Apr 24 | Greene-Sulzberger Gabrielle | Common Stock | Grant | Acquire A | No | No | 750.77 | 13 | 9.76 k | 2,128 |
News
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
24 Apr 24
Market Whales and Their Recent Bets on LLY Options
23 Apr 24
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
22 Apr 24
Eli Lilly Acquires New Injectable Medicine Manufacturing Facility From Nexus Pharmaceuticals; Lilly Estimates That Production At Injectable Medicine Manufacturing Facility Could Begin At The End Of 2025; No Financial Terms Disclosed
22 Apr 24
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
18 Apr 24
Press releases
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
22 Apr 24
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
19 Apr 24
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
18 Apr 24
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
17 Apr 24
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
16 Apr 24